DoD Taking Applications For $75K Horizon Grant

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The Department of Defense is taking applications for its Horizon Award, which offers up to $75,000 in funding to support junior-level scientists to conduct impactful research with the mentorship of an experienced cancer researcher.

The award is for principal investigators, both pre-doctoral candidates and postdoctoral fellows are eligible, and mentors that have a strong record of funding and publications. The PI and mentor must be from the same organization.

They must address at least one of the congressionally directed FY15 PRCRP Topic Areas and are encouraged to address at least one of the FY15 PRCRP Military Relevance Focus Areas. Research applications in the areas of breast, prostate, lung (excluding mesothelioma), or ovarian cancer will not be accepted.

The FY15 PRCRP Topic Areas are: cancers of the kidney, liver, pancreas, stomach or colorectal tract; melanoma and other skin cancers; myeloproliferative disorders; listeria vaccines for cancer; mesothelioma; and neuroblastoma. Liver and stomach cancer have been newly added for 2015.

The FY15 Military Relevance Focus Areas are: Militarily relevant risk factors associated with cancer (e.g., ionizing radiation, chemicals, infectious agents, and environmental carcinogens); and gaps in cancer prevention, screening, early detection, diagnosis, treatment, and/or survivorship that may affect the general population but have a particularly profound impact on the health and well-being of military members, veterans, and their beneficiaries.

Full applications are due Aug. 11. Clinical trials are not allowed and preliminary data are not required. The maximum period of performance is one year.

A pre-application is required through the electronic Biomedical Research Application Portal at http://eBRAP.org prior to the pre-application deadline.

Program announcements and general application instructions are available at www.grants.gov.

YOU MAY BE INTERESTED IN

The University of California, San Francisco and global oncology communities mourn the death of Felix Y. Feng, MD, a radiation oncologist and a leading figure in genitourinary cancer research. A professor of radiation oncology, urology and medicine, and vice chair of translational research at the UCSF Helen Diller Family Comprehensive Cancer Center, Feng died from cancer on Dec.10, 2024. He was 48.
The late Felix Feng, MD (center) with researchers Jonathan Chou, MD, PhD (left) and Lisa Chesner, PhD (right), in 2019.Photo by Noah BergerFelix Y. Feng, a genitourinary cancer research leader, died on Dec. 10, 2024. He was 48.This article is republished with permission by NRG Oncology.Dr. Feng was the former NRG Oncology Genitourinary Cancer Committee chair and an RTOG Foundation member. After years of dedicated and enthusiastic commitment to the NRG and previously the RTOG Genitourinary Cancer Committee, chairing or co-chairing 13 research protocols for NRG and RTOG, Dr. Feng was appointed committee chair in March 2018, following in the footsteps of Dr. Howard Sandler, his mentor. Dr. Feng was also a member of the RTOG Foundation Board of Directors.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login